Loading
A phase 1/2 trial of PM8002 in small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07325136 by Bristol-Myers Squibb, with 240 participants planned, started 2026-02-03 and due to reach its primary completion in 2029-04-23. Interventions recorded: BMS-986525, Pumitamig. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.